David Planchard, Thoracic Oncologist, Professor at the University Paris Saclay and Head of the Thoracic Cancer Group at the Gustave Roussy, shared a post on LinkedIn:
“Very clear and comprehensive presentation on perioperative TKIs by Hidehito Horinouchi. Still many questions, but osimertinib has revolutionized the approach (ADAURA), as it continues to do for EGFRmut advanced stage (FLAURA and FLAURA2 are both the standard of care 1st line).”
You Can Also Read Inside ESMO Asia 2025 with David Planchard on OncoDaily.
